Opioid Kullanımı ve Aşırı Dozların Önlenmesi: Klinik, Toplumsal ve Politika Düzeyindeki Müdahaleler

Authors

Hatice Eftal Şeyda Kanal
https://orcid.org/0000-0002-0311-050X

References

Harper D. Etymology of opium. Online Etymology Dictionary. [Online] https://www.etymonline.com/word/opium [Accessed: 17th August 2026]

Merriam-Webster. Opioid. Merriam-Webster.com Dictionary. [Online] https://www.merriam-webster.com/dictionary/opioid [Accessed: 17th August 2026]

Oxford University Press. Opiate, n. & adj. Oxford English Dictionary. [Online] https://www.oed.com/dictionary/opiate_n [Accessed: 17th August 2026]

Chalise U. The poppy plant: phytochemistry & pharmacology. Indo Global Journal of Pharmaceutical Sciences. 2015;5(1):58–65. doi:10.35652/IGJPS.2015.24

Carlin MG, Dean JR, Ames JM. Opium alkaloids in harvested and thermally processed poppy seeds. Frontiers in Chemistry. 2020;8:737. doi:10.3389/fchem.2020.00737

Degenhardt L, Grebely J, Stone J, et al. Global patterns of opioid use and dependence: harms to populations, interventions, and future action. The Lancet. 2019;394(10208):1560–1579. doi:10.1016/S0140-6736(19)32229-9

United Nations Office on Drugs and Crime. World Drug Report 2023. United Nations; 2023. [Online] https://www.unodc.org/unodc/en/data-and-analysis/world-drug-report-2023.html [Accessed: 17th August 2026]

World Health Organization. Lexicon of Alcohol and Drug Terms. Geneva: World Health Organization; 1994. [Online] https://www.who.int/publications/i/item/9241544686 [Accessed: 5th September 2026]

World Health Organization. Opioid overdose. 2025. [Online] https://www.who.int/news-room/fact-sheets/detail/opioid-overdose [Accessed: 17th August 2026]

National Academies of Sciences, Engineering, and Medicine. Medications for opioid use disorder save lives. Washington, DC: The National Academies Press; 2019. doi:10.17226/25310

United Nations Office on Drugs and Crime. World Drug Report 2025. United Nations; 2025. [Online] https://www.unodc.org/unodc/en/data-and-analysis/world-drug-report-2025.html [Accessed: 17th August 2026]

Zhu DT, Kwon YIC, Lai A, et al. Global burden of disease due to opioid, amphetamine, cocaine, and cannabis use disorders, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. PLOS ONE. 2025;20(8):e0328276. doi:10.1371/journal.pone.0328276

European Union Drugs Agency. European Drug Report 2025: Trends and Developments. Luxembourg: Publications Office of the European Union; 2025. doi:10.2810/3504283 [Online] https://www.euda.europa.eu/publications/european-drug-report/2025_en [Accessed: 17th August 2026]

Effatpanah M, Seyedmirzaei H, Karami H, et al. Burden of opioid use disorder in the Middle East and North Africa (MENA): findings from Global Burden of Disease (GBD) study. Journal of Health, Population and Nutrition. 2025;44:296. doi:10.1186/s41043-025-01029-4

Emniyet Genel Müdürlüğü, Narkotik Suçlarla Mücadele Başkanlığı. 2025 Türkiye Uyuşturucu Raporu: Eğilimler ve Gelişmeler. Ankara: Emniyet Genel Müdürlüğü; 2025.

Emniyet Genel Müdürlüğü, Narkotik Suçlarla Mücadele Daire Başkanlığı. 2020 Türkiye Uyuşturucu Raporu: Eğilimler ve Gelişmeler. Ankara: Emniyet Genel Müdürlüğü; 2020.

Emniyet Genel Müdürlüğü, Narkotik Suçlarla Mücadele Daire Başkanlığı. 2021 Türkiye Uyuşturucu Raporu: Eğilimler ve Gelişmeler. Ankara: Emniyet Genel Müdürlüğü; 2021.

Emniyet Genel Müdürlüğü, Narkotik Suçlarla Mücadele Başkanlığı. 2022 Türkiye Uyuşturucu Raporu: Eğilimler ve Gelişmeler. Ankara: Emniyet Genel Müdürlüğü; 2022.

Emniyet Genel Müdürlüğü, Narkotik Suçlarla Mücadele Başkanlığı. 2023 Türkiye Uyuşturucu Raporu: Eğilimler ve Gelişmeler. Ankara: Emniyet Genel Müdürlüğü; 2023.

Emniyet Genel Müdürlüğü, Narkotik Suçlarla Mücadele Başkanlığı. 2024 Türkiye Uyuşturucu Raporu: Eğilimler ve Gelişmeler. Ankara: Emniyet Genel Müdürlüğü; 2024.

Swingler M, Donadoni M, Unterwald EM, et al. Molecular and cellular basis of mu-opioid receptor signaling: mechanisms underlying tolerance and dependence development. Frontiers in Neuroscience. 2025;19:1597922. doi:10.3389/fnins.2025.1597922

Centers for Disease Control and Prevention. Opioid use disorder: diagnosis. 2024. [Online] https://www.cdc.gov/overdose-prevention/hcp/clinical-care/opioid-use-disorder-diagnosis.html [Accessed: 17th August 2026]

Bruun Ericson Ø, Eide D, Lobmaier P, et al. Mortality risk and causes of death among people who use opioids in a take-home naloxone cohort. Drug and Alcohol Dependence. 2024;255:111087. doi:10.1016/j.drugalcdep.2024.111087

Hser YI, Mooney LJ, Saxon AJ, et al. High Mortality Among Patients With Opioid Use Disorder in a Large Healthcare System. Journal of Addiction Medicine. 2017;11(4):315–319. doi:10.1097/ADM.0000000000000312

World Health Organization. WHO Expert Committee on Drug Dependence: forty-third report. WHO Technical Report Series, No. 1034. Geneva: World Health Organization; 2021. [Online] https://www.who.int/publications/i/item/9789240023024 [Accessed: 17th August 2026]

World Health Organization, United Nations Office on Drugs and Crime. UNODC-WHO Stop-Overdose-Safely (S-O-S) project implementation in Kazakhstan, Kyrgyzstan, Tajikistan and Ukraine: summary report. Geneva: World Health Organization; 2021. [Online] https://iris.who.int/items/77fbdf0f-34a7-48fc-8b7a-2a08b640a388 [Accessed: 17th August 2026]

Larney S, Tran LT, Leung J, et al. All-cause and cause-specific mortality among people using extramedical opioids: a systematic review and meta-analysis. JAMA Psychiatry. 2020;77(5):493–502. doi:10.1001/jamapsychiatry.2019.4170

Santo T Jr, Campbell G, Gisev N, et al. Prevalence of mental disorders among people with opioid use disorder: A systematic review and meta-analysis. Drug and Alcohol Dependence. 2022;238:109551. doi:10.1016/j.drugalcdep.2022.109551

Ashrafioun L, Zerbo KRA, Bishop TM, et al. Opioid use disorders, psychiatric comorbidities, and risk for suicide attempts among veterans seeking pain care. Psychological Medicine. 2020;50(12):2107–2112. doi:10.1017/S0033291719002307

Dowell D, Ragan KR, Jones CM, et al. CDC clinical practice guideline for prescribing opioids for pain—United States, 2022. MMWR Recommendations and Reports. 2022;71(3):1–95. doi:10.15585/mmwr.rr7103a1

Strang J, McDonald R, Campbell G, et al. Take-home naloxone for the emergency interim management of opioid overdose: the public health application of an emergency medicine. Drugs. 2019;79(13):1395–1418. doi:10.1007/s40265-019-01154-5

Giglio RE, Li G, DiMaggio CJ. Effectiveness of bystander naloxone administration and overdose education programs: a meta-analysis. Injury Epidemiology. 2015;2(1):10. doi:10.1186/s40621-015-0041-8

Ellingwood NT, McGraw M, Chandra K. Naloxone use and outcomes in prehospital and emergency department care. Cureus. 2026;18(2):e104074. doi:10.7759/cureus.104074

Rzasa Lynn R, Galinkin JL. Naloxone dosage for opioid reversal: current evidence and clinical implications. Therapeutic Advances in Drug Safety. 2018;9(1):63–88. doi:10.1177/2042098617744161

Bart G. Maintenance medication for opiate addiction: the foundation of recovery. Journal of Addictive Diseases. 2012;31(3):207–225. doi:10.1080/10550887.2012.694598

Connery HS. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harvard Review of Psychiatry. 2015;23(2):63–75. doi:10.1097/HRP.0000000000000075

Bell J, Strang J. Medication treatment of opioid use disorder. Biological Psychiatry. 2020;87(1):82–88. doi:10.1016/j.biopsych.2019.06.020

Lee JD, Nunes EV Jr, Novo P, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. The Lancet. 2018;391(10118):309–318. doi:10.1016/S0140-6736(17)32812-X

Wakeman SE, Larochelle MR, Ameli O, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Network Open. 2020;3(2):e1920622. doi:10.1001/jamanetworkopen.2019.20622

Evren C. Current status of buprenorphine/naloxone maintenance treatment in Istanbul, Turkey. Addicta. 2014;1(2):48–63. doi:10.15805/addicta.2014.1.2.026

T.C. Sağlık Bakanlığı, Sağlık Hizmetleri Genel Müdürlüğü. Alkol ve Madde Kullanım Bozuklukları Tedavi ve İzlem Klinik Protokolü. Ankara: T.C. Sağlık Bakanlığı; 2022. [Online] https://dosyamerkez.saglik.gov.tr/Eklenti/42286/0/alkolmaddekullbozuklklaritedaviizlemkp05012022pdf.pdf [Accessed: 25th August 2026].

World Health Organization. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Geneva: World Health Organization; 2009. [Online] https://www.who.int/publications/i/item/9789241547543 [Accessed: 17th August 2026]

Dugosh K, Abraham A, Seymour B, et al. A systematic review on the use of psychosocial interventions in conjunction with medications for the treatment of opioid addiction. Journal of Addiction Medicine. 2016;10(2):93–103. doi:10.1097/ADM.0000000000000193

Bolívar HA, Klemperer EM, Coleman SRM, et al. Contingency management for patients receiving medication for opioid use disorder: a systematic review and meta-analysis. JAMA Psychiatry. 2021;78(10):1092–1102. doi:10.1001/jamapsychiatry.2021.1969

Durpoix A, Rolling J, Coutelle R, et al. Psychotherapies in opioid use disorder: toward a step-care model. Journal of Neural Transmission. 2024;131(5):437–452. doi:10.1007/s00702-023-02720-8

Lin LA, Bohnert ASB, Blow FC, et al. Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration. Addiction. 2021;116(1):96–104. doi:10.1111/add.15116

European Union Drugs Agency. Harm reduction—the current situation in Europe: European Drug Report 2026. Lisbon: European Union Drugs Agency; 2026. [Online] https://www.euda.europa.eu/publications/european-drug-report/2026/harm-reduction_en [Accessed: 17th August 2026]

Fischer LS, Asher A, Stein R, et al. Effectiveness of naloxone distribution in community settings to reduce opioid overdose deaths among people who use drugs: a systematic review and meta-analysis. BMC Public Health. 2025;25(1):1135. doi:10.1186/s12889-025-22210-8

Abdelal R, Banerjee AR, Carlberg-Racich S, et al. Real-world study of multiple naloxone administration for opioid overdose reversal among bystanders. Harm Reduction Journal. 2022;19(1):49. doi:10.1186/s12954-022-00627-3

Dietze P, Gerra G, Poznyak V, et al. An observational prospective cohort study of naloxone use at witnessed overdoses, Kazakhstan, Kyrgyzstan, Tajikistan and Ukraine. Bulletin of the World Health Organization. 2022;100(3):187–195. doi:10.2471/BLT.21.286450

Walker S, Dietze P, Poznyak V, et al. More than saving lives: qualitative findings of the UNODC/WHO Stop Overdose Safely (S-O-S) project. International Journal of Drug Policy. 2022;100:103482. doi:10.1016/j.drugpo.2021.103482

Gariépy G, Prowse RKM, Plouffe R, et al. Supervised consumption sites and population-level overdose mortality: a systematic review of recent evidence, 2016–2024. Health Promotion and Chronic Disease Prevention in Canada. 2025;45(9):357–366. doi:10.24095/hpcdp.45.9.02

Harocopos A, Gibson BE, Saha N, et al. First 2 months of operation at first publicly recognized overdose prevention centers in US. JAMA Network Open. 2022;5(7):e2222149. doi:10.1001/jamanetworkopen.2022.22149

Panagiotoglou D, Lim J. Using synthetic controls to estimate the population-level effects of Ontario’s recently implemented overdose prevention sites and consumption and treatment services. International Journal of Drug Policy. 2022;110:103881. doi:10.1016/j.drugpo.2022.103881

Bard H, Chatterjee A. Fit-for-purpose solutions beyond supervised injection offer the next stage of harm reduction for the US drug epidemic. Discover Public Health. 2025;22:393. doi:10.1186/s12982-025-00806-0

Sherman SG, Morales KB, Park JN, et al. Acceptability of implementing community-based drug checking services for people who use drugs in three United States cities: Baltimore, Boston and Providence. International Journal of Drug Policy. 2019;68:46–53. doi:10.1016/j.drugpo.2019.03.003

Rose CG, Kulbokas V, Carkovic E, et al. Contextual factors affecting the implementation of drug checking for harm reduction: a scoping literature review from a North American perspective. Harm Reduction Journal. 2023;20(1):124. doi:10.1186/s12954-023-00856-0

Karamouzian M, Dohoo C, Forsting S, et al. Evaluation of a fentanyl drug checking service for clients of a supervised injection facility, Vancouver, Canada. Harm Reduction Journal. 2018;15(1):46. doi:10.1186/s12954-018-0252-8

Karch L, Tobias S, Schmidt C, et al. Results from a mobile drug checking pilot program using three technologies in Chicago, IL, USA. Drug and Alcohol Dependence. 2021;228:108976. doi:10.1016/j.drugalcdep.2021.108976

Barratt MJ, Kowalski M, Maier LJ, et al. Global review of drug checking services operating in 2017. Drug Policy Modelling Program Bulletin No. 24. Sydney: National Drug and Alcohol Research Centre, UNSW Sydney; 2018. [Online] https://archive-ndarc.med.unsw.edu.au/resource/bulletin-no-24-global-review-drug-checking-services-operating-2017 [Accessed: 17th August 2026]

Trans-European Drug Information Project. TEDI network: drug checking services. 2022. [Online] https://tedinetwork.org/ [Accessed: 17th August 2026]

Rouhani S, Park JN, Morales KB, et al. Harm reduction measures employed by people using opioids with suspected fentanyl exposure in Boston, Baltimore, and Providence. Harm Reduction Journal. 2019;16(1):39. doi:10.1186/s12954-019-0311-9

Tilhou AS, Zaborek J, Baltes A, et al. Differences in drug use behaviors that impact overdose risk among individuals who do and do not use fentanyl test strips for drug checking. Harm Reduction Journal. 2023;20(1):41. doi: 10.1186/s12954-023-00767-0

Tsai AC, Kiang MV, Barnett ML, et al. Stigma as a fundamental hindrance to the United States opioid overdose crisis response. PLOS Medicine. 2019;16(11):e1002969. doi:10.1371/journal.pmed.1002969

Werder K, Curtis A, Reynolds S, et al. Addressing bias and stigma in the language we use with persons with opioid use disorder: a narrative review. Journal of the American Psychiatric Nurses Association. 2022;28(1):9–22. doi:10.1177/10783903211050121

Kelly JF, Westerhoff CM. Does it matter how we refer to individuals with substance-related conditions? A randomized study of two commonly used terms. International Journal of Drug Policy. 2010;21(3):202–207. doi:10.1016/j.drugpo.2009.10.010

Zwick J, Appleseth H, Arndt S. Stigma: how it affects the substance use disorder patient. Substance Abuse Treatment, Prevention, and Policy. 2020;15(1):50. doi:10.1186/s13011-020-00288-0

Edwards KA, Merlin JS, Webster F, et al. Breaking barriers: addressing opioid stigma in chronic pain and opioid use disorder. PAIN. 2025;166(6):1268–1273. doi:10.1097/j.pain.0000000000003475

International Narcotics Control Board. Report of the International Narcotics Control Board for 2012. New York: United Nations; 2013. [Online] https://www.incb.org/incb/en/publications/annual-reports/annual-report-2012.html [Accessed: 17th August 2026]

Fink DS, Schleimer JP, Sarvet A, et al. Association between prescription drug monitoring programs and nonfatal and fatal drug overdoses: a systematic review. Annals of Internal Medicine. 2018;168(11):783–790. doi:10.7326/M17-3074

Patrick SW, Fry CE, Jones TF, et al. Implementation of prescription drug monitoring programs associated with reductions in opioid-related death rates. Health Affairs. 2016;35(7):1324–1332. doi:10.1377/hlthaff.2015.1496

Rhodes E, Wilson M, Robinson A, et al. The effectiveness of prescription drug monitoring programs at reducing opioid-related harms and consequences: a systematic review. BMC Health Services Research. 2019;19(1):784. doi:10.1186/s12913-019-4642-8

T.C. Sağlık Bakanlığı, Kastamonu İl Sağlık Müdürlüğü. 26 Haziran Dünya Uyuşturucu Kullanımı ve Kaçakçılığı ile Mücadele Günü. 2021. [Online] https://kastamonuism.saglik.gov.tr/TR-186350/26-haziran-dunya-uyusturucu-kullanimi-ve-kacakciligi-ile-mucadele-gunu.html [Accessed: 17th August 2026]

T.C. Sağlık Bakanlığı, Sağlık Bilgi Sistemleri Genel Müdürlüğü. Reçetem Sistemi hakkında: tüm SBYS üreticilerinin dikkatine. 2020. [Online] https://kayittescil.saglik.gov.tr/TR-64318/06032020-recetem-sistemi-hk-tum-sbys-ureticilerine.html [Accessed: 17th August 2026]

Anderson JF, Reinsmith-Jones K, Brooks WM Jr, et al. Paradigm shift in responding to drug users and addicts: from a criminal justice to a public health approach. International Journal of Social Science Studies. 2017;5(5):1–15. doi:10.11114/ijsss.v5i5.2349

Goulka J, del Pozo B, Beletsky L. From public safety to public health: re-envisioning the goals and methods of policing. Journal of Community Safety and Well-Being. 2021;6(1):22–27. doi:10.35502/jcswb.184

Knaphus-Soran E, Brown R. LEAD fidelity framework. Version 2. Seattle: LEAD Proof of Concept Project; 2022. [Online] https://leadbureau.org/wp-content/uploads/2023/02/LEADFidelityFramework-v2_9-29-22.pdf [Accessed: 17th August 2026]

Cook AK, Worcman N. Confronting the opioid epidemic: public opinion toward the expansion of treatment services in Virginia. Health & Justice. 2019;7(1):13. doi:10.1186/s40352-019-0095-8

Green TC, Clarke J, Brinkley-Rubinstein L, et al. Postincarceration fatal overdoses after implementing medications for addiction treatment in a statewide correctional system. JAMA Psychiatry. 2018;75(4):405–407. doi:10.1001/jamapsychiatry.2017.4614

Türkiye Cumhuriyeti. 5237 sayılı Türk Ceza Kanunu. Resmî Gazete. 12 Ekim 2004;(25611). Madde 191. [Online] https://mevzuat.adalet.gov.tr/mevzuat/103228 [Accessed: 17th August 2026]

T.C. Adalet Bakanlığı. Denetimli Serbestlik Hizmetleri Yönetmeliği. Resmî Gazete. 10 Kasım 2021;(31655). Madde 71. [Online] https://cte.adalet.gov.tr/Home/SayfaDetay/yonetmelikler [Accessed: 17th August 2026]

Latronica JR. Increasing access to medications for opioid use disorder: policy analysis and proposals. Journal of Addictive Diseases. 2021;39(3):421–424. doi:10.1080/10550887.2021.1882650

McGinty EE, White SA, Eisenberg MD, et al. US payment policy for medications to treat opioid use disorder: landscape and opportunities. Health Affairs Scholar. 2024;2(3):qxae024. doi:10.1093/haschl/qxae024

T.C. Sağlık Bakanlığı. Sosyal güvencem yok, ne yapabilirim? ALO 191 Uyuşturucu ile Mücadele Danışma ve Destek Hattı. 2023. [Online] https://alo191.saglik.gov.tr/TR-50359/sosyal-guvencem-yok-ne-yapabilirim.html [Accessed: 17th August 2026]

Published

November 18, 2026

License

License